Perdaman Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 12.03 Cr
as on 15-11-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 5.20%
(FY 2023)
- Profit 18.89%
(FY 2023)
- Ebitda 32.32%
(FY 2023)
- Net Worth 3.20%
(FY 2023)
- Total Assets 30.08%
(FY 2023)
About Perdaman Pharmaceuticals
The Corporate was formerly known as Perdaman Financial Services And Holdings Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 12.03 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Perdaman Pharmaceuticals Private Limited India is Shubham Namdev as COMPANY SECRETARY. Vikas Rambal, Sarojni Rambal, Manoj Rambal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233DL2008PTC174864
- Company No.
174864
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Perdaman Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shubham Namdev | Company Secretary | 20-Dec-2022 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Rambal  | Director | 04-Mar-2008 | Current |
| Sarojni Rambal | Director | 04-Mar-2008 | Current |
| Manoj Rambal | Director | 15-May-2010 | Current |
| Usha Rambal | Director | 14-Oct-2010 | Current |
| Samir Garud | Director | 20-Jun-2013 | Current |
Financial Performance of Perdaman Pharmaceuticals.
Perdaman Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.2% increase. The company also saw a substantial improvement in profitability, with a 18.89% increase in profit. The company's net worth moved up by a moderate rise of 3.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Perdaman Pharmaceuticals?
In 2023, Perdaman Pharmaceuticals had a public holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sunrise International Labs LimitedActive 31 years 10 monthsVikas Rambal, Sarojni Rambal and 3 more are mutual person
Shirdi Bio Fuels Private LimitedActive 17 years 2 monthsVikas Rambal, Sarojni Rambal and 2 more are mutual person
- Perdaman Renewable Energy Private LimitedActive 15 years 9 months
Vikas Rambal, Manoj Rambal and 1 more are mutual person
- Perdaman Corporate Services Private LimitedActive 16 years 5 months
Vikas Rambal and Usha Rambal are mutual person
- Perdaman Engineering And Consultancy Services Private LimitedActive 15 years 6 months
Vikas Rambal and Usha Rambal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Perdaman Pharmaceuticals?
Unlock and access historical data on people associated with Perdaman Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Perdaman Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Perdaman Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
